Business Context and Reporting Period
This Form 8-K is a current report filed by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) on May 4, 2023. The filing serves to disclose an investor presentation furnished to shareholders and potential investors under Regulation FD (Item 7.01). The company is incorporated in Israel and its American Depositary Shares trade on the Nasdaq Capital Market under the symbol BVXV.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure notice regarding an investor presentation rather than a financial statement report.
Material Changes
No material financial changes or operational updates are detailed within the text of this filing. The primary event is the distribution of an investor presentation (Exhibit 99.1) which may contain updated information.
Guidance, Outlook, and Risks
The filing notes that the information contained in the attached investor presentation may be amended or updated at any time. The text explicitly states that the information in Item 7.01 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference into other filings unless expressly stated. No specific guidance, risks, or contingencies are enumerated in the cover page text.
Investor Verification Checklist
- Verify the correct registrant name is BiondVax Pharmaceuticals Ltd., not Scinai Immunotherapeutics Ltd.
- Review the attached Exhibit 99.1 (Investor Presentation) for actual financial data, clinical updates, and strategic outlook, as this 8-K only serves as a notice of its existence.
- Confirm the trading symbol BVXV on the Nasdaq Capital Market.
- Note that the presentation materials are not legally "filed" under Section 18 of the Exchange Act unless specifically referenced in a future filing.